BioCryst Pharmaceuticals, Inc. (BCRX)

NASDAQ

$7.59

+$0.02 (0.33%)

Today

No price data available for this timeframe.

Key Statistics

Day Range

$7.43$7.92

Open $7.63

52 Week Range

$6.00$11.31

Previous Close $7.57

Market Cap1.60B

Volume4.40M

Avg Volume4.99M

P/E (TTM)-181.83

EPS (TTM)$-0.04

Dividend / YieldN/A

Dividend StreakN/A

Latest Press Releases for BioCryst Pharmaceuticals, Inc.

DEC122025

BioCryst Announces FDA Approval of ORLADEYO® (berotralstat) Oral Pellets, First and Only Oral Prophylactic Treatment for Patients with HAE Aged 2 to

Source: GlobeNewsWire•4 days ago

– ORLADEYO now first and only targeted oral prophylactic therapy for patients with HAE aged 2 and older – -Oral pellet formulation provides child-friendly method of administration- –Showed early and sustained reductions in monthly attack rates in APe...

DEC42025

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Source: GlobeNewsWire•12 days ago

RESEARCH TRIANGLE PARK, N.C., Dec. 04, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst's board of directors granted four newly-hired employees stock options to purchas...

DEC32025

BioCryst Receives Early Termination of HSR Waiting Period for Astria Acquisition

Source: GlobeNewsWire•13 days ago

RESEARCH TRIANGLE PARK, N.C., Dec. 03, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that it has received early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976,...

NOV62025

BioCryst Presents New Data at ACAAI Highlighting Burden of HAE on Pediatric Patients and Caregivers and Sustained Reduction of Attacks in Children Treated with One Year of ORLADEYO® (berotralstat)

Source: GlobeNewsWire•40 days ago

– Findings highlight negative psychosocial impact of HAE attacks and resulting ED/hospital visits on pediatric patients and their caregivers – – ORLADEYO oral granules demonstrated early and sustained reduction in HAE attacks over one year of trea...

NOV52025

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Source: GlobeNewsWire•41 days ago

RESEARCH TRIANGLE PARK, N.C., Nov. 05, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst's board of directors granted three newly-hired employees restricted stock units ...

NOV52025

BioCryst to Present at Upcoming Investor Conference

Source: GlobeNewsWire•41 days ago

RESEARCH TRIANGLE PARK, N.C., Nov. 05, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company plans to present at the Jefferies Global Healthcare Conference in London on Wednesday, November 19, 2025, a...

NOV32025

BioCryst Reports Third Quarter 2025 Financial Results and Provides Business Update

Source: GlobeNewsWire•43 days ago

—Q3 2025 ORLADEYO net revenue of $159.1 million (+37 percent y-o-y)— —Q3 2025 operating profit of $29.6 million (+285 percent y-o-y); non-GAAP operating profit of $51.7 million (+107 percent y-o-y); continued improvement in non-GAAP operating profit...

OCT232025

BioCryst to Present New Pediatric HAE Data at the American College of Allergy, Asthma & Immunology 2025 Annual Scientific Meeting

Source: GlobeNewsWire•54 days ago

RESEARCH TRIANGLE PARK, N.C., Oct. 23, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present four abstracts at the Annual Scientific Meeting of the American College of Allergy, Asthma & I...

OCT202025

BioCryst to Report Third Quarter 2025 Financial Results on November 3

Source: GlobeNewsWire•57 days ago

RESEARCH TRIANGLE PARK, N.C., Oct. 20, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its third quarter 2025 financial results on Monday, November 3, 2025....

OCT172025

Astria Therapeutics Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Astria Therapeutics, Inc. - ATXS

Source: Business Wire•59 days ago

NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Astria Therapeutics, Inc. (NasdaqGM: ATXS) to BioC...